N@N

CELERA CORP (NASDAQ:CRA), Up By 28.82% ($1.81) From $6.280 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish C

^{Published on 2011-03-18 08:01:52 - WOPRAI}
 

March 18, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, January 26th 2011 stating that CELERA CORP (NASDAQ:CRA) was expected to go Up due to the Bullish conditions presented in the following report. Click here to view the BUYINS.NET report: http://www.buyins.net/tools/symbol_stats.php?sym=cra

At the time this story was written, CELERA CORP (NASDAQ:CRA) is Up By $1.81 (28.82%) since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following specific fundamental or technical events may follow a predictable pattern. Many companies stock price histories show random or unpredictable movements around certain events. But some seem to repeat the same pattern quarter after quarter, year after year. We use powerful computers to uncover those events and correlations to generate predictions with high probabilities of generating very specific returns within very specific time periods.

The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

CELERA CORP (NASDAQ:CRA) - Celera Corporation offers personalized disease management through a combination of products and services primarily in the United States. The companys Lab Services segment provides a portfolio of clinical laboratory tests and disease management services designed to help physicians improve cardiovascular disease treatment regimens for their patients. This segment offers clinical laboratory testing services that characterize and monitor cardiovascular disease risks; and personalized and ongoing therapeutic compliance education. It also provides principal tests, including LDL-S3GGE test that measures low-density lipoprotein (LDL) size as a subclass distribution divided in seven regions and characterizes the amount of LDL distributed in these regions; HDL-S10GGE test that measures high-density lipoprotein (HDL) size as a subclass distribution divided across five HDL regions and characterizes the amount of HDL distributed in these regions; Kinesin-Like Protein 6 (KIF6) test, which detects a variant in a gene called KIF6; and LPA genotype test to detect a variant of the LPA gene known as 4399Met. Its Products segment develops and manufactures molecular diagnostic products for disease detection, prediction of disease predisposition, monitoring of disease progression and disease severity, and determination of patient responsiveness to treatments. Celera Corporation has a strategic alliance with Abbott Laboratories to discover, develop, and commercialize molecular diagnostic products for disease detection, prediction of disease predisposition, disease progression monitoring, and therapy selection. The companys Corporate segment licenses small molecule drug development programs and Life Technologies intellectual property to third parties for use in the diagnostic field; and establishes collaborations to develop cancer therapies based on its proteomics discoveries. Celera Corporation was founded in 1998 and is headquartered in Alameda, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor market-maker surveillance system tracking Level II market-makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 30 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies specifically for this report, but may have been compensated up to $1,200 per month in the past for unrelated data or report services. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net